Tag Archives: biotechnology news

Wyeth v. Abbott Labs. – Picking Plaintiff’s Poison

Posted on June 28, 2013 by Warren Woessner

In July of 2011, I wrote a post for this blog on BSC v. J&J, a Fed. Cir. decision in which four J&J patents claiming stents eluting rapamycin, a drug that inhibits restenosis after balloon angioplasty, were held invalid for … Continue reading →

Posted in Enablement, Written Description Requirements (WDR) | Tagged , , , , , , , , , , | 1 Comment

Association For Molecular Pathology V Myriad Genetics – An Isolated Local Difficulty?

Posted on June 14, 2013 by Warren Woessner

Paul Cole, Professor of Intellectual Property Law at Bournemouth University and European Patent Attorney at Lucas & Co, Warlingham, Surrey, UK discusses yesterdays Myriad ruling by the Supreme Court. How does yesterday’s Supreme Court decision match international opinion on the patentability … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Supreme Court Rules In Myriad On Patentability Of DNA

Posted on June 13, 2013 by Warren Woessner

Today, the Supreme Court ruled that a naturally occurring DNA sequence is a product of nature, and not patent-eligible simply because it has been “isolated.” (A copy of the ruling can be found at the end of this post.) However, the … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 4 Comments

Supreme Court Decides Bowman v. Monsanto for Monsanto

Posted on May 15, 2013 by Warren Woessner

On May 13th, a unanimous Court found that the doctrine of patent exhaustion “does not allow the purchaser to make new copies of the patented invention.” [A copy of decision is at the end of this post.] In this case, the patented … Continue reading →

Posted in Ag Biotechnology | Tagged , , , , , , , , | 1 Comment